Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S H Appel

Showing results (241-250 of 249) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 249 results.
European Journal of Neurology|January 16, 2010
ALS disease onset may occur later in patients with pre-morbid diabetes mellitusA Jawaid, A R Salamone, A M Strutt, et al.
European Journal of Neurology|October 1, 2010
Does apolipoprotein E genotype modify the clinical expression of ALS?A Jawaid, M Poon, A M Strutt, et al.
Journal of Neurochemistry|November 10, 2001
Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosisD R Beers, B K Ho, L Siklós, et al.
Neurology|October 22, 2008
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosisS H Appel, J I Engelhardt, J S Henkel, et al.
Neuron|September 1, 1996
Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelinationL E Warner, M J Hilz, S H Appel, et al.
Neurology|May 20, 2009
SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophyM C Hannibal, E K Ruzzo, L R Miller, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Neurology|August 27, 2003
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisM E Cudkowicz, J M Shefner, D A Schoenfeld, et al.
Pageof 25

Showing results (241-250 of 249) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 249 results.
European Journal of Neurology|January 16, 2010
ALS disease onset may occur later in patients with pre-morbid diabetes mellitusA Jawaid, A R Salamone, A M Strutt, et al.
European Journal of Neurology|October 1, 2010
Does apolipoprotein E genotype modify the clinical expression of ALS?A Jawaid, M Poon, A M Strutt, et al.
Journal of Neurochemistry|November 10, 2001
Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosisD R Beers, B K Ho, L Siklós, et al.
Neurology|October 22, 2008
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosisS H Appel, J I Engelhardt, J S Henkel, et al.
Neuron|September 1, 1996
Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelinationL E Warner, M J Hilz, S H Appel, et al.
Neurology|May 20, 2009
SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophyM C Hannibal, E K Ruzzo, L R Miller, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Neurology|August 27, 2003
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisM E Cudkowicz, J M Shefner, D A Schoenfeld, et al.
Pageof 25